Related Experiment Videos
Advances in pain therapeutics
Philip LoGrasso1, Jeffrey McKelvy
1Avera Pharmaceuticals, 12730 High Bluff Drive, Suite 160, San Diego, CA 92130, USA.
Current Opinion in Chemical Biology
|August 28, 2003
Summary
Researchers are exploring novel molecular targets for neuropathic pain, including N-methyl-D-aspartate receptor subtypes and voltage-gated sodium channels. Promising preclinical data suggest these targets could lead to new pain therapies.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Neuropathic pain is a complex condition with significant unmet treatment needs.
- Identifying specific molecular targets is crucial for developing effective therapies.
Purpose of the Study:
- To review recent advancements in defining molecular targets for neuropathic pain.
- To evaluate the therapeutic potential of N-methyl-D-aspartate receptor subtypes and voltage-gated sodium channels.
Main Methods:
- Literature review of recent preclinical and genetic studies.
- Analysis of data on selective and non-selective channel blockers.
Main Results:
- N-methyl-D-aspartate receptor subtypes (glycine and NR2B sites) show promise, with selective antagonists demonstrating efficacy in animal models.
- Selective blockers for the tetrodotoxin-resistant voltage-gated sodium channel (Na(v) 1.8) are still under development, but evidence suggests potential.
Conclusions:
- Novel molecular targets, including NMDA receptor subtypes and Na(v) 1.8 channels, represent promising avenues for neuropathic pain treatment.
- Further research into selective Na(v) 1.8 channel blockers is warranted.